IBO 8-K: Acquisition

Filed with the SEC on · accession 0001493152-26-053017

IBO filed a 8-K (current report) with the SEC on Nov 18, 2026. Impact BioMedical completed a business combination with Zoar Limited (formerly Dr Ashleys Limited) and Zoar Labs Limited, becoming a wholly-owned subsidiary of PubCo.

Summary of the filing

Impact BioMedical completed a business combination with Zoar Limited (formerly Dr Ashleys Limited) and Zoar Labs Limited, becoming a wholly-owned subsidiary of PubCo. Impact stockholders received approximately 4.80% of PubCo, while the Zoar shareholder received approximately 94.02%.

Key details

Aggregate PubCo Ordinary Shares issued to former Impact BioMedical stockholders as Merger Consideration$8.6M
PubCo Ordinary Shares issued to the Zoar Shareholder in the Share Exchange$168.0M
PubCo Ordinary Shares issued to Frank D. Heuszel as Compensation Shares$22K
PubCo Ordinary Shares issued to DSS, Inc.$228K
PubCo Ordinary Shares issued to BMI Capital International LLC$1.8M
Registrant; merged with merger sub and became a wholly-owned subsidiary of pubcoImpact BioMedical Inc.
Cayman islands exempted company; became pubco and parent of the surviving corporationZoar Limited (formerly Dr Ashleys Limited)
Merger sub; merged with and into impact biomedicalDr Ashleys Nevada Sub, Inc.
Cayman islands exempted company; became a wholly-owned subsidiary of pubco via share exchangeZoar Labs Limited (formerly Dr Ashleys Bio Labs Limited)
Received 228,000 pubco ordinary shares in connection with the share exchangeDSS, Inc.
Received 1,800,000 pubco ordinary shares, representing approximately 1.00% of pubco, in connection with the share exchangeBMI Capital International LLC
Chief executive officer of impact biomedicalFrank D. Heuszel
Sole shareholder of zoarKanans Visvanats (a.k.a. Kannan Vishwanatth)

✦ Ask GOAX AI about this filing — what it means for IBO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for IBO?

Click here

Frequently asked questions

What did IBO file with the SEC on Nov 18, 2026?

IBO filed a 8-K (Acquisition). Impact BioMedical completed a business combination with Zoar Limited (formerly Dr Ashleys Limited) and Zoar Labs Limited, becoming a wholly-owned subsidiary of PubCo. Impact stockholders received approximately 4.80% of PubCo, while the Zoar shareholder received approximately 94.02%.

What does a acquisition mean for IBO stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other IBO SEC filings

Get alerts when IBO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days